Neo Triage reproduces every scanner, bug bounty and AI-generated finding against the real asset, then sets severity from proven impact

SAN FRANCISCO, Oct. 26, 2026 /PRNewswire/ — ProjectDiscovery, a leader in vulnerability detection and autonomous security testing, today announced the general availability of Neo Triage: a new capability in its Neo platform that validates every incoming security finding by safely reproducing it against the live asset. Every verdict comes with the exact requests and responses that prove it, so teams can go straight to fixing what’s real.

Neo Triage gives every team one place to triage findings from every source, including:

Dynamic triage: Runs safe, non-destructive tests from an isolated sandbox to reproduce each finding against the live assetVerdicts with evidence: Marks every finding valid, duplicate, needs more information, informative, not applicable or spam, and attaches the exact requests and responses as proofSeverity from proven impact: Sets severity from the impact Neo proved and from the asset’s context, including the data behind it, how exposed it is and what else it reachesOne queue for every source: Pulls findings from HackerOne, GitHub security advisories, security mailboxes, Wiz, Qualys, Orca and any other tool with an API onto one boardFix and retest: Suggests a fix, drafts a reply to the researcher and retests automatically once the fix shipsInsights: Tracks open backlog, SLA status, time to zero, weekly remediation and the quality of each source

“Today, AI has made finding vulnerabilities cheap, and security teams spend hours reproducing each finding by hand,” said Rishi Sharma, CEO and Co-founder of ProjectDiscovery. “In the next 6-12 months, triage and the bottleneck it causes will be the biggest problem security teams will face. Scanners, AI code review and AI-assisted bug hunting now generate findings faster than teams can review them, leaving most organizations with thousands – or even millions, of open findings. The hard part now is deciding which findings matter, and a score can’t make that decision. Proof can. Neo Triage tests every finding against the real asset and hands the team a verdict with the evidence attached, so teams spend their time on decisions instead of on reproducing reports.”

Manual triage takes anywhere from 15 minutes to four hours per finding. ProjectDiscovery estimates that for a 100,000-finding backlog, Neo Triage turns roughly 50,000 hours of manual work, the equivalent of 25 people for a year, into about 8,300 hours of verdict review. Every Neo tier – including its free, community tier – includes the full Triage product.

Neo itself is free to get started, with monthly usage included and no time limit. Anyone can sign up and run useful workflows immediately, whether that means triaging findings from their own scanners or running a prompt that checks whether they’re exposed to a newly disclosed vulnerability. As their usage grows, teams can move to Pro or Enterprise tiers under zero data retention.

For more information on Neo Triage, visit: https://projectdiscovery.io/blog/introducing-neo-triage 

About ProjectDiscovery

ProjectDiscovery is an open source cybersecurity company that built the security toolchain trusted by more than 100,000 practitioners worldwide. The company created Nuclei, the most widely used open source vulnerability scanner with over 10 billion scans run, along with a suite of modular tools including Subfinder, httpx, and Naabu that security teams use to map attack surfaces and identify exploitable vulnerabilities. Building on that foundation, ProjectDiscovery offers Neo, an AI-powered security testing platform that unifies SAST, DAST, and automated penetration testing to help teams move from finding vulnerabilities to verifying and fixing them. ProjectDiscovery is a winner of the RSAC Innovation Sandbox 2025 and a Black Hat Asia 2025 award recipient. Learn more at projectdiscovery.io.

View original content to download multimedia:https://www.prnewswire.com/news-releases/projectdiscovery-introduces-neo-triage-replacing-static-risk-scores-with-proven-exploitability-302918866.html

SOURCE ProjectDiscovery

SAN FRANCISCO, Oct. 26, 2026 /PRNewswire/ — Corgi, an AI-native insurance carrier and financial infrastructure company, today announced the appointment of Morgan Bevin as VP, Public Affairs Officer. Bevin will help lead Corgi’s government affairs efforts, working at the intersection of insurance, financial services, and emerging technology as the company continues to expand its insurance offerings and infrastructure.

Bevin joins Corgi from Sternhell Group, where she served as Principal, advising clients on government relations across financial services and technology. Her work spans public policy, regulatory strategy, and government affairs for financial institutions, technology companies, and organizations across the financial services sector.

Prior to Sternhell Group, Bevin was a Consultant at Wachsman, providing strategic advisory and communications services to financial services and emerging technology companies. She also served as a Professional Staff Member on the U.S. House of Representatives Committee on Financial Services, where she helped lead the Committee’s financial technology agenda. Earlier in her career, she was a Financial Services Policy Fellow for Representative French Hill (AR-02).

Bevin’s background in financial services policy and government relations comes as Corgi continues to build modern insurance infrastructure for businesses navigating increasingly complex risks. As AI reshapes the insurance industry, Corgi is focused on developing technology-driven underwriting and insurance products while engaging with the regulatory and policy landscape surrounding the sector.

“We’re excited to have Morgan join Corgi as we continue to grow our business and expand our presence across the insurance industry,” said Jeremy Eisemann, Chief External Affairs Officer and Deputy General Counsel at Corgi. “Her experience across government, financial services, and emerging technology will be valuable as we work with policymakers and industry stakeholders to support the next generation of insurance.”

About Corgi

Corgi Insurance is an AI-native insurance carrier and financial infrastructure company. The company combines proprietary underwriting technology, modern insurance infrastructure, and in-house claims capabilities to provide coverage for businesses across a growing range of industries.

Media Contact:
Corgi Press
press@corgi.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/corgi-insurance-appoints-morgan-bevin-as-vp-public-affairs-officer-302918837.html

SOURCE Corgi

Automated system enables rapid, reproducible formulation screening with minimal sample consumptionCompletes the NanoCalibur® Series (Mini, Lab, Pro, GMP), supporting a seamless scale-up path from early research to GMP manufacturing

BOSTON, Oct. 26, 2026 /PRNewswire/ — MEPSGEN US, Inc., a global innovator in drug delivery system platforms, today announced the launch of NanoCalibur® Mini, an automated system for small-volume nanoparticle formulation designed for early-stage drug discovery and development.

Nanoparticles are delivery vehicles that carry therapeutic payloads to target sites in the body, and they are central to next-generation modalities such as mRNA and gene therapies. Early-stage research requires repeated testing of many raw materials and process conditions, so the ability to generate fast, consistent results from limited material is essential.

NanoCalibur® Mini formulates lipid nanoparticles (LNPs) and polymeric nanoparticles at volumes of 0.1–3 mL. Built on MEPSGEN‘s proprietary microfluidic technology, it delivers precise, stable microfluidic flow control for rapid and highly reproducible formulation. Researchers can choose between two single-use microfluidic cartridges, 0.1–0.4 mL and 0.4–3 mL, to match their application, from early formulation screening through a range of preclinical studies. By enabling many formulation conditions to be tested quickly with minimal material, Mini helps accelerate development timelines while reducing reagent consumption and experimental costs.

One production architecture, from discovery to GMP

With the addition of Mini, the NanoCalibur® Series now spans four systems (Mini, Lab, Pro, and GMP), allowing customers to select the right platform for their development stage and production scale.

The defining feature of the series is a consistent formulation environment at every scale. NanoCalibur® Mini to Lab and to GMP uses the same microfluidic mixing pattern, with the same structure and dimensions. Rather than redesigning the mixer or changing the formulation conditions as production grows, NanoCalibur® increases throughput by parallelizing identical mixing units. This design is intended to reduce the need for process re-optimization during scale-up and technology transfer, while preserving nanoparticle quality and batch-to-batch reproducibility.

Protecting payload integrity at scale

In large-scale nanoparticle manufacturing, the high flow rates required for throughput can generate shear forces that damage sensitive payloads such as mRNA and reduce the potency. The NanoCalibur® Series is engineered to maintain stable shear conditions as production scales, helping preserve payload integrity and deliver consistent nanoparticle quality. More importantly, preserving payload potency will have the high potential to reduce the dose required for therapeutic effect, possibly addressing the high-dosage toxicity such as LNPs.

Launch promotion

To mark the launch of NanoCalibur® Mini, MEPSGEN will run a series of promotional offers through the end of the year for research institutions and pharmaceutical and biotechnology companies evaluating the system. Details will be announced on the MEPSGEN website and the company’s official LinkedIn page.

“With NanoCalibur® Mini, we have extended our product lineup so that we can support customers more precisely at every stage, from early research through GMP manufacturing,” said YongTae Kim, CEO of MEPSGEN. “We will continue to broaden the applications and customer base of the NanoCalibur® Series and strengthen our position in the global nanomedicine manufacturing market.”

About MEPSGEN

MEPSGEN is a biotech company headquartered in Seoul, South Korea, with office in Cambridge, MA. The company was co-founded in 2019 by current CEO YongTae (Tony) Kim and Professor Robert Langer from MIT, a world-renowned expert in drug delivery and biomaterials who has pioneered numerous breakthroughs in controlled-release systems.

The company specializes in microphysiological system (MPS) and drug delivery system platforms based on its proprietary microfluidics technology. Its NanoCalibur® Series offers scalable nanoparticle formulation systems that support drug discovery, preclinical research, and GMP manufacturing, while its MPS platforms, including the MEPS-X Series and ProMEPS®, recreate the physiological function of human organs for New Approach Methodologies (NAMs). Together, they help pharmaceutical and biotech companies, universities, hospitals, and research institutions improve the efficiency and success rate of drug development.

For more information, please visit www.mepsgen.com or reach out to info@mepsgen-us.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/mepsgen-launches-nanocalibur-mini-for-small-volume-nanoparticle-formulation-302916579.html

SOURCE MEPSGEN US, Inc.